Adverse events with systemic or intravitreal anti-VEGF drugs

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Part of the "short- and long-term monitoring of the benefit-risk profile of intravitreal use of anti-VEGF drugs through network of clinical and administrative data" project (CUP-H56D15000440005).

Cutroneo PM, et al. Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System. Drug Safety : 5 Jun 2017. Available from: URL: http://dx.doi.org/10.1007/s40264-017-0553-y

Adverse events with systemic or intravitreal anti-VEGF drugs. Reactions Weekly 1656, 8 (2017). https://doi.org/10.1007/s40278-017-31338-0

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.